Abstract
Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Current Pharmaceutical Design
Title: Urokinase Receptor and Integrin Interactions
Volume: 9 Issue: 19
Author(s): Matthias C. Kugler, Ying Wei and Harold A. Chapman
Affiliation:
Keywords: urokinase, integrin, adhesion, receptor
Abstract: Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Export Options
About this article
Cite this article as:
Kugler C. Matthias, Wei Ying and Chapman A. Harold, Urokinase Receptor and Integrin Interactions, Current Pharmaceutical Design 2003; 9 (19) . https://dx.doi.org/10.2174/1381612033454658
DOI https://dx.doi.org/10.2174/1381612033454658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Nuclear Long Non-Coding RNAs as Epigenetic Regulators in Cancer
Current Medicinal Chemistry Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
Current Pharmaceutical Biotechnology Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design The Identification and Biochemical Properties of the Catalytic Specificity of a Serine Peptidase Secreted by Aspergillus fumigatus Fresenius
Protein & Peptide Letters Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design